A booster dose of Pfizer’s COVID-19 vaccine raised the level of antibodies in children ages 5 through 11, including a massive increase in antibodies that fight the Omicron variant, the company announced Thursday.In addition to a significant increase in protection against the now-dominant Omicron variant, the booster — administered six months after a two-dose primary vaccine — also increases protection against the original strain, the drugmaker said.The ongoing clinical trial has shown a 36-fold increase in protection from Omicron over an unboosted, two-dose vaccination.
Load More
Load More